New pathogenic paradigms in inflammatory bowel disease

Antonio Di Sabatino, Paolo Biancheri, Laura Rovedatti, Thomas T MacDonald, Gino R Corazza

Research output: Contribution to journalReview articlepeer-review

70 Citations (Scopus)


Recent progresses in basic science have opened new pathogenic scenarios in inflammatory bowel disease. The T helper cell type (Th)1/Th2 paradigm has been outdated thanks to the advances in understanding the function of Th17 cells. Innate immunity, nonimmune cells, and defective tolerogenic mechanisms play a no less crucial role than do adaptive immunity, immune cells, and hyperactivation of effector mechanisms. These new paradigms, together with the no longer "static" but "dynamic" vision of intestinal inflammation, highlight new possible therapeutic targets in inflammatory bowel disease.

Original languageEnglish
Pages (from-to)368-371
Number of pages4
JournalInflammatory Bowel Diseases
Issue number2
Early online date27 Apr 2011
Publication statusPublished - 1 Feb 2012


  • Adaptive Immunity
  • Humans
  • Immune Tolerance
  • Immunity, Innate
  • Immunity, Mucosal
  • Inflammatory Bowel Diseases/immunology
  • Interleukin-17/immunology
  • Interleukin-23/immunology
  • Th1 Cells/immunology
  • Th17 Cells/immunology
  • Th2 Cells/immunology

Cite this